Welcome, Guest. Please login or register.
Did you miss your activation email?
September 04, 2010, 08:34:52 PM
Home Help Search Login Register
 Don't have much time to browse? Click here to view the most recent posts.

0
5
7
3
 enrolled and counting...
Three products now FDA-approved!
- Cinryze, approved to prevent HAE attacks.
- Berinert, approved for treating acute facial and abdominal HAE attacks
- Kalbitor, approved for treating acute attacks in patients 16 yrs and older. The product is delivered through subcutaneous injections

Please contact the HAEA's Patient Services group for more information

+  HAEA Forum
|-+  HAE Message Forum
| |-+  HAE Clinical trials
| | |-+  DX-88 (ecallantide) 		« previous next »
Pages: [1] Print
Author Topic: DX-88 (ecallantide)  (Read 360 times)
lmgardner
Jr. Member
**
Posts: 2
« on: November 01, 2009, 08:30:37 AM »
I have been involved in the clinical trials with DX-88 for years and have been anxiously awaiting its FDA approval.  Now my study coordinator has informed me that it will not be approved for home administration.  I am so disappointed and discouraged.  When I have an abdominal attack the last thing that I want to do is leave the comforts of home and head to my MD office or ER. 

I sent two letters to Paul Fletcher of Dyax but have not received a response.  I was not able to attend the conference in Orlando.  Was there any new information released regarding DX-88?  Is my information accurate?  Is there anything that I can do to challenge this decision?
Logged
Pages: [1] Print 
« previous next »
 


Login with username, password and session length

Powered by SMF 2.0 Beta 4 | SMF © 2006–2008, Simple Machines LLC
Support for the HAE Association's 2009 Activities Provided by